SEOUL, Feb. 12 (Korea Bizwire) — Samsung Bioepis Co., the biosimilar drug development arm of Samsung Group, said Thursday it plans to launch its ophthalmology biosimilar, Opuviz, in the United States in 2027. Opuviz, a biosimilar referencing Eylea, a blockbuster drug developed by U.S.-based Regeneron Pharmaceuticals Inc., received sales approval from the U.S. Food and [...]
SEOUL, Dec. 26 (Korea Bizwire) — South Korea’s two leading biosimilar makers, Celltrion and Samsung Bioepis, are converging in global scale but diverging sharply in how they produce and sell their medicines, according to a new industry analysis released this week. A report by Korea Ratings said the contrasting strategies have become a defining feature of [...]
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in the U.S. Partnership supports Teva’s Pivot to Growth strategy and adds to its broad biosimilar portfolio INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (Korea Bizwire) – Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. [...]
First time in Samsung’s history to name a non-founder female Chief Executive Officer INCHEON, South Korea, Nov. 27, 2024 (Korea Bizwire) – Samsung Bioepis Co., Ltd. today announced that Kyung-Ah Kim, who has been serving as Executive Vice President and Development Division Leader, has been named as President and Chief Executive Officer of Samsung Bioepis. [...]
Report highlights key progress and achievements across three pillars: access to medicines, R&D innovation, and product quality and patient safety 430,000 patients have been treated with Samsung Bioepis’ biosimilars across 40 countries in 2023 In 10 countries, our biosimilars have created social impact worth approximately 2.5 trillion KRW (1.9 billion USD) in 2023 The company [...]
INCHEON, Korea, April 05, 2024 (Korea Bizwire) – Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company’s proposed biosimilar referencing Keytrudai (pembrolizumab). The Phase 3 clinical trial for SB27 is a randomized, double-blind, parallel group, multicenter studyii to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and Keytruda [...]
Enters into a commercialization agreement for SB17, ustekinumab biosimilar candidate, in Europe and North America Partnership to support Samsung Bioepis pipeline expansion and provide increased access to biosimilars INCHEON, Korea, Sept. 11, 2023 (Korea Bizwire) – Samsung Bioepis Co., Ltd. today announced that it has entered into a commercialization agreement with Sandoz for SB17, [...]
SEOUL, Aug. 2 (Korea Bizwire) — Samsung Bioepis Co., a biosimilar medicine developer under Samsung Group, has been in talks with Biogen Inc. to buy the U.S. biotech firm’s biosimilar business unit, industry sources said Wednesday. Through the deal with the Nasdaq-listed firm, Samsung Bioepis seeks to secure a direct sales network in the United [...]
INCHEON, Korea, June 30 (Korea Bizwire) — Samsung Bioepis Co., Ltd. today released its 2023 sustainability report, highlighting its progress toward building more sustainable and socially responsible practices in research and development (R&D), clinical trials, manufacturing, and supply chain management. “The consequences of the COVID-19 pandemic such as global supply chain disruptions, as well as [...]
INCHEON, Korea, April 17 (Korea Bizwire) — Samsung Bioepis Co., Ltd. today released the first edition of its Biosimilar Market Report which explores latest market trends for all biosimilars commercially available in the United States. The first quarterly report details the most recent price trends of all molecules for which biosimilars have launched, along with [...]